Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“I’m not a leukemia AML doc. So Im struggling to understand this. The PARADIGM study is a randomized phase II, not phase III.
Are these results with Aza/Ven vs 7+3 sufficient to be considered paradigm changing to toss out decades of practice?
What am I missing? What are the caveats for community practice?”
Nihar Desai, Chief Fellow of Hematology at Princess Margaret Cancer Centre, shared a post by Vincent Rajkumar, adding:
“Not practice changing, but hard to ignore! Aza-Ven gets patients to CR/CRc with far less toxicity, and is more realistic in LMIC/community settings. IC arm also received Vyxeos and seems to have more p53 mutated patients, so the comparison is not clean. Still, the signal is hard to dismiss.”
More posts featuring Vincent Rajkumar and Nihar Desai.
